Published in Am J Gastroenterol on September 01, 2004
Pathological evolution of hepatitis C virus-"Healthy carriers". World J Gastroenterol (2008) 0.80
Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels. PLoS One (2016) 0.77
Chronic hepatitis C and normal ALT: considerations for treatment. Am J Gastroenterol (2004) 0.75
Hepatitis C treatment & management. J Med Life (2014) 0.75
Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2005) 0.75
Is liver biopsy mandatory in children with chronic hepatitis C? World J Gastroenterol (2007) 0.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology (2007) 3.40
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology (2014) 3.29
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Clinical practice. Microscopic hematuria. N Engl J Med (2003) 2.96
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg (2009) 2.95
The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol (2006) 2.93
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76
A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol (2002) 2.75
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology (2004) 2.64
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol (2013) 2.44
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Steroid use in acute liver failure. Hepatology (2013) 2.23
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol (2007) 2.02
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Evaluating the potential living liver donor. Liver Transpl (2004) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology (2011) 1.63
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Hepatitis C virus and liver transplantation. Clin Liver Dis (2006) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl (2003) 1.57
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology (2007) 1.56
Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl (2013) 1.52
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. Dig Dis Sci (2005) 1.41
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C. AIDS Read (2003) 1.38
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read (2006) 1.38
Sorafenib: where do we go from here? Hepatology (2010) 1.38
Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol (2013) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol (2013) 1.25
Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transpl (2002) 1.22
Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology (2004) 1.21
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol (2010) 1.17
The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant (2005) 1.16
Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl (2002) 1.15
Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl (2010) 1.15
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci (2012) 1.12
Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer (2010) 1.12
Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Point-of-care photomicroscopy of urine. N Engl J Med (2011) 1.09
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses (2010) 1.08
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol (2009) 1.06
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol (2011) 1.06
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci (2004) 1.04
Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation (2012) 1.03
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol (2007) 1.03
Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci (2007) 1.03
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol (2003) 1.02
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol (2005) 1.02